Expression of cytokeratin 19 in prostatic adenocarcinoma: a systematic review

Expression of cytokeratin 19 in prostatic adenocarcinoma: a systematic review

Abstract Background Cytokeratins are intracellular proteins known as diagnostic biomarkers or prognostic factors for certain cancers. Cytokeratin 19 (CK-19) expression has been proven to have prognostic value for some cancers, but its relationship with others, such as prostate cancer (PCa), remains...

Full description

Saved in:

Bibliographic Details
Main Authors:	Sina Shahshenas, Seyyed Mohammad Hosseini, Hossein Yarmohammadi, Masood Soltanipur, Mohammadreza Jalali Nadoushan
Format:	Article
Language:	English
Published:	BMC 2025-01-01
Series:	BMC Cancer
Subjects:	Cytokeratin 19 CK-19 expression Prostatic adenocarcinoma (PAC) Prostate cancer (PCa) Gleason scores and grades
Online Access:	https://doi.org/10.1186/s12885-025-13456-x
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Exploring the efficacy of AMACR, ERG, and AR immunostains in prostatic adenocarcinoma and their association with novel grade groups
by: Mohamed O. Andarawi, et al.
Published: (2025-02-01)

Intermediate risk prostate tumors contain lethal subtypes
by: William L. Harryman, et al.
Published: (2025-01-01)

A case of stromal sarcoma of the prostate with the incidental detection of prostate adenocarcinoma
by: Shang Xu, et al.
Published: (2025-03-01)

Radiomics based Machine Learning Models for Classification of Prostate Cancer Grade Groups from Multi Parametric MRI Images
by: Fatemeh Zandie, et al.
Published: (2024-12-01)

Diagnostic Accuracy of Serum Prostate Specific Antigen and Gleason Score in Determining the Presence of Skeletal Metastasis in Prostate Cancer Patients: a Pakistani Perspective
by: Taimoor Nasir, et al.
Published: (2023-04-01)

Serendipitous Diagnosis of Adenocarcinoma of the Mandible Metastasized from the Prostate: A Case Report
by: Krishna Satpathy, et al.
Published: (2024-12-01)

Atypical Metastases from Prostate Cancer: Alpha-Methylacyl-Coenzyme A Racemase (AMACR) as a Potential Molecular Target in Prostate-Specific Membrane Antigen-Negative Prostate Adenocarcinoma
by: Ilham Badrane, et al.
Published: (2024-12-01)

Incidence of prostate adenocarcinoma in transurethral resection of the prostate patients
by: Yahia Ghazwani, et al.
Published: (2025-01-01)

Mucin-producing urothelial-type adenocarcinoma of the prostate with a gene mutation characteristic of intestinal adenocarcinoma: case report and literature review
by: Ao Yu, et al.
Published: (2025-01-01)

Clinical assessment of urinary prostate cancer antigen 3 in Chinese population: a large-scale, prospective and multicenter study
by: Xuan Shu, et al.
Published: (2024-12-01)

Evaluating the feasibility of AI-predicted bpMRI image features for predicting prostate cancer aggressiveness: a multi-center study
by: Kexin Wang, et al.
Published: (2025-01-01)

Comparison of molecular analysis results determined by next-generation sequencing to immunohistochemical indicators and clinicopathological parameters in prostate adenocarcinomas
by: Merve Çırak Balta, et al.
Published: (2024-04-01)

Comparative Study of Gleason 7 (3+4) and (4+3) Prostatic Adenocarcinomas with Prognostic Criteria and Immunohistochemical Profiles of AMACR, PSA and Ki-67
by: Clarice F. E. M. Osório, et al.
Published: (2025-01-01)

A comprehensive analysis of erectile dysfunction prevalence and the impact of prostate conditions on ED among US adults: evidence from NHANES 2001-2004
by: Yuhao Zhang, et al.
Published: (2025-01-01)

Effectiveness of hormone therapy in patients with prostate cancer. Regional experience
by: P. G. Berezin, et al.
Published: (2020-12-01)

Association between prostate-specific antigen density and prostate cancer prediction among Nigerian men
by: Abudu EK, et al.
Published: (2025-01-01)

Development and Validation of an MRI‐Based Radiomics Nomogram to Predict the Prognosis of De Novo Oligometastatic Prostate Cancer Patients
by: Wen‐Qi Liu, et al.
Published: (2024-12-01)

Dual‐Enhanced SERS Satellite Immuno‐Nanocomplex for Multiple PSA‐Mediated PHI Assay Toward Clinical Prostate Cancer Screening
by: Dong Chen, et al.
Published: (2025-02-01)

The factors impacting on Gleason score upgrading in prostate cancer with initial low Gleason scores
by: Tzu-Heng Huang, et al.
Published: (2025-02-01)

The Novel Histological Prostatic Inflammation Score Helps Defining the Association Between Stromal and Glandular Inflammation with the Risk of Prostate Cancer at Prostate Biopsy
by: Ugo Giovanni Falagario, et al.
Published: (2025-01-01)

Current biomarkers of prostate cancer
by: I. A. Aboian, et al.
Published: (2021-12-01)

Specific immunohistochemical expression of Mmp-26 in prostatic adenocarcinoma
by: ROMILDO LUCIANO DA SILVA, et al.
Published: (2025-01-01)

Exploring the causal role of plasma metabolites and metabolite ratios in prostate cancer: a two-sample Mendelian randomization study
by: Changzhou Feng, et al.
Published: (2025-01-01)

Potential clinical application of the cancer antigen CA‑62 for differential diagnosis of prostate cancer and benign prostatic hyperplasia at the elevated prostate‑specific antigen
by: Zh. R. Cherkasova, et al.
Published: (2023-03-01)

Prediction of biochemical prostate cancer recurrence from any Gleason score using robust tissue structure and clinically available information
by: Laura E. Marin, et al.
Published: (2025-02-01)

Prostatic Artery Embolization: A Systematic Review Article
by: Pooja Atkuri, et al.
Published: (2025-01-01)

Comparison of Finasteride and Dutasteride on Risk of Prostate Cancer in Patients with Benign Prostatic Hyperplasia: A Pooled Analysis of 15 Real-world Databases
by: Dae Yul Yang, et al.
Published: (2025-01-01)

A Rare Metastasis of Prostate Cancer
by: İlkin Hamid-Zada, et al.
Published: (2024-07-01)

Prostate Cancer Screening: Is it Recommended in 2024?
by: Dr. Ali Thwaini
Published: (2024-12-01)

Analysis of the predictive value of the prostate-specific antigen-to-neutrophil ratio for the diagnosis of prostate cancer
by: Yuxuan Chen, et al.
Published: (2025-01-01)

Comparison of Post Biopsy Pathology and Post Radical Prostatectomy Pathology in Patients with Prostate Cancer Detected After Fusion Biopsy
by: Serdar Göktaş, et al.
Published: (2023-10-01)

Malondialdehyde in benign prostate hypertrophy: a useful marker?
by: Rosaria Alba Merendino, et al.
Published: (2003-01-01)

IMPROVING THE QUALITY OF PROSTATE TRANSURETHRAL RESECTION IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA THROUGH INTRAOPERATIVE TRANSRECTAL ULTRASOUND MONITORING OF THE REMOVED TISSUE VOLUME
by: V. B. Filimonov, et al.
Published: (2019-06-01)

Metastatic gastric adenocarcinoma in prostate: A case report
by: Naru Shimizu, et al.
Published: (2025-03-01)

The “prostate-pelvic syndrome” theory used in patients with type-III prostatitis and its correlation with prostate volume
by: Xiao-Ma Zhang, et al.
Published: (2025-01-01)

Tegaserod maleate exerts anti-tumor effects on prostate cancer via repressing sonic hedgehog signaling pathway
by: Maoping Cai, et al.
Published: (2025-01-01)

Correlation of clinically significant prostate cancer sites across multiparametric MRI, prostate biopsy, and whole-mount pathology for optimal prostate biopsy strategy
by: Matteo Pacini, et al.
Published: (2025-02-01)

Exploring the prognostic significance of lactate-mitochondria-related genes in prostate cancer
by: Yuan Wang, et al.
Published: (2025-01-01)

The initial results of MRI-TRUS fusion prostate biopsy in high volume tertiary center
by: Smrkolj Tomaz, et al.
Published: (2024-11-01)

Influence of Regular Statin Intake on Prostate‐Specific Antigen Values, Prostate Cancer Incidence and Overall Survival in a Prospective Screening Trial (ERSPC Aarau)
by: Alkiviadis Papagiannakis, et al.
Published: (2025-01-01)